- Home
- FFC vs SEPN Comparison
FFC vs SEPN Comparison
Compare FFC & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFC
- SEPN
- Stock Information
- Founded
- FFC 1983
- SEPN 2022
- Country
- FFC United States
- SEPN United States
- Employees
- FFC N/A
- SEPN N/A
- Industry
- FFC Trusts Except Educational Religious and Charitable
- SEPN
- Sector
- FFC Finance
- SEPN
- Exchange
- FFC Nasdaq
- SEPN NYSE
- Market Cap
- FFC 781.9M
- SEPN 631.0M
- IPO Year
- FFC N/A
- SEPN 2024
- Fundamental
- Price
- FFC $15.93
- SEPN $6.10
- Analyst Decision
- FFC
- SEPN Buy
- Analyst Count
- FFC 0
- SEPN 4
- Target Price
- FFC N/A
- SEPN $33.00
- AVG Volume (30 Days)
- FFC 164.1K
- SEPN 420.0K
- Earning Date
- FFC 01-01-0001
- SEPN 03-27-2025
- Dividend Yield
- FFC 6.79%
- SEPN N/A
- EPS Growth
- FFC N/A
- SEPN N/A
- EPS
- FFC N/A
- SEPN N/A
- Revenue
- FFC N/A
- SEPN $1,075,000.00
- Revenue This Year
- FFC N/A
- SEPN N/A
- Revenue Next Year
- FFC N/A
- SEPN N/A
- P/E Ratio
- FFC N/A
- SEPN N/A
- Revenue Growth
- FFC N/A
- SEPN 611.92
- 52 Week Low
- FFC $11.90
- SEPN $4.17
- 52 Week High
- FFC $14.96
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- FFC 45.24
- SEPN N/A
- Support Level
- FFC $16.03
- SEPN N/A
- Resistance Level
- FFC $16.20
- SEPN N/A
- Average True Range (ATR)
- FFC 0.15
- SEPN 0.00
- MACD
- FFC -0.01
- SEPN 0.00
- Stochastic Oscillator
- FFC 31.25
- SEPN 0.00
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.